{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:25:47Z","timestamp":1789244747035,"version":"build-2803163510"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science, Research and Innovation Fund (NSRF), Thailand through the Fundamental Fund of Khon Kaen University"},{"name":"Postgraduate Study Scholarship from Faculty of Medicine, Khon Kaen University, Thailand"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Cholangiocarcinoma (CCA), particularly when associated with <jats:italic><jats:italic>Opisthorchis viverrini<\/jats:italic><\/jats:italic> infection, is often diagnosed at a late stage and exhibits high resistance to chemotherapy, notably gemcitabine. While kinesin family member 18A (KIF18A) is upregulated in opisthorchiasis-associated CCA, its precise function, especially in gemcitabine-resistant CCA, remains largely unexplored. Herein, expression of KIF18A in relation to survival and progression was assayed by TCGA database mining and immunohistochemistry of a tissue microarray derived from 84 CCA patients. For functional study, KIF18A was suppressed in gemcitabine-resistant CCA cells (KKU-213B<jats:sup>GemR<\/jats:sup>) using a CRISPR\/Cas9 technique, followed by cellular and molecular analyses. Our results showed that KIF18A was highly expressed in CCA tissues compared to normal counterparts. Its expression was significantly correlated with tumor size and histological type of CCA but not with overall survival time. <jats:italic><jats:italic>In vitro<\/jats:italic><\/jats:italic>, KIF18A expression levels were increased in CCA cell lines, particularly KKU-213B<jats:sup>GemR<\/jats:sup>. Suppression of KIF18A significantly inhibited colony formation, migration and invasion by KKU-213B<jats:sup>GemR<\/jats:sup> cells. In addition, KIF18A knockdown led to a significant increase in the sub-G1 population, indicating the occurrence of cellular apoptosis. Flow cytometry confirmed that suppression of KIF18A significantly induced early apoptotic cell death of KKU-213B<jats:sup>GemR<\/jats:sup> cells. Suppression of KIF18A dramatically downregulated the expression of key oncogenic and survival signaling proteins, including PI3K (total and p-PI3K), Akt (total and p-Akt), mTOR (total and p-mTOR), NF-\u03baB (total and p-NF-\u03baB) and Bcl-2 in KKU-213B<jats:sup>GemR<\/jats:sup> cells. Taken together, our findings suggest that KIF18A plays crucial roles in promoting the progression and survival of gemcitabine-resistant CCA cells, partly by modulating PI3K\/Akt\/mTOR and NF-\u03baB pathways. Therefore, despite its lack of prognostic utility, KIF18A represents a promising therapeutic target for improving treatment outcomes in CCA patients, especially those who do not respond to gemcitabine treatment.<\/jats:p>","DOI":"10.1371\/journal.pone.0334147","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:24:46Z","timestamp":1760549086000},"page":"e0334147","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Suppression of kinesin family member-18A diminishes progression and induces apoptotic cell death of gemcitabine-resistant cholangiocarcinoma cells by modulating PI3K\/Akt\/mTOR and NF-\u03baB pathways"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9735-028X","authenticated-orcid":true,"given":"Pakornkiat","family":"Tanasuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phonpilas","family":"Thongpon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasitorn","family":"Chomwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6276-5765","authenticated-orcid":true,"given":"Suppakrit","family":"Kongsintaweesuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Pinlaor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thatsanapong","family":"Pongking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-0583","authenticated-orcid":true,"given":"Sasithorn","family":"Watcharadetwittaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawalit","family":"Pairojkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-9371","authenticated-orcid":true,"given":"Kitti","family":"Intuyod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"9","key":"pone.0334147.ref001","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"JM Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"pone.0334147.ref002","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"SI Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"pone.0334147.ref003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"J Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"pone.0334147.ref004","doi-asserted-by":"crossref","first-page":"850732","DOI":"10.3389\/fonc.2022.850732","article-title":"Overcome drug resistance in cholangiocarcinoma: new insight into mechanisms and refining the preclinical experiment models","volume":"12","author":"Q Zheng","year":"2022","journal-title":"Front Oncol"},{"issue":"19","key":"pone.0334147.ref005","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.3390\/ijerph17196938","article-title":"Quality of life of cancer patients treated with chemotherapy","volume":"17","author":"A Lewandowska","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"pone.0334147.ref006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cub.2007.02.036","article-title":"The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression","volume":"17","author":"MI Mayr","year":"2007","journal-title":"Curr Biol"},{"issue":"21","key":"pone.0334147.ref007","doi-asserted-by":"crossref","first-page":"10271","DOI":"10.18632\/oncotarget.2082","article-title":"High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma","volume":"5","author":"W Liao","year":"2014","journal-title":"Oncotarget"},{"key":"pone.0334147.ref008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/ITT.S497284","article-title":"Integrated profiling delineated KIF18A as a significant biomarker associated with both prognostic outcomes and immune response in pancreatic cancer","volume":"14","author":"K Nan","year":"2025","journal-title":"Immunotargets Ther"},{"key":"pone.0334147.ref009","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2021.04.020","article-title":"KIF18A knockdown reduces proliferation, migration, invasion and enhances radiosensitivity of esophageal cancer","volume":"557","author":"L-X Qian","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"pone.0334147.ref010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3892\/etm.2023.11853","article-title":"KIF18A interacts with PPP1CA to promote the malignant development of glioblastoma","volume":"25","author":"J Yang","year":"2023","journal-title":"Exp Ther Med"},{"issue":"1","key":"pone.0334147.ref011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3892\/etm.2016.3335","article-title":"Elevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma","volume":"12","author":"QI Chen","year":"2016","journal-title":"Exp Ther Med"},{"issue":"7","key":"pone.0334147.ref012","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/iub.2030","article-title":"Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma","volume":"71","author":"Y Zhong","year":"2019","journal-title":"IUBMB Life"},{"issue":"1","key":"pone.0334147.ref013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-018-4978-5","article-title":"Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+\u2009breast cancer","volume":"173","author":"LH Alfarsi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"pone.0334147.ref014","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.21037\/tcr.2019.09.38","article-title":"KIF18A promotes head and neck squamous cell carcinoma invasion and migration via activation of Akt signaling pathway","volume":"8","author":"G Liu","year":"2019","journal-title":"Transl Cancer Res"},{"issue":"1","key":"pone.0334147.ref015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12957-018-1342-5","article-title":"The role of kinesin KIF18A in the invasion and metastasis of hepatocellular carcinoma","volume":"16","author":"W Luo","year":"2018","journal-title":"World J Surg Oncol"},{"issue":"4","key":"pone.0334147.ref016","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/cancers17040685","article-title":"Targeting kinesins for therapeutic exploitation of chromosomal instability in lung cancer","volume":"17","author":"C Zhang","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0334147.ref017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/CBM-130296","article-title":"Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma","volume":"12","author":"R Rucksaken","year":"2012","journal-title":"Cancer Biomark"},{"issue":"1","key":"pone.0334147.ref018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s43018-023-00699-5","article-title":"Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers","volume":"5","author":"M Payton","year":"2024","journal-title":"Nat Cancer"},{"issue":"1","key":"pone.0334147.ref019","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41467-024-55300-z","article-title":"Targeting chromosomally unstable tumors with a selective KIF18A inhibitor","volume":"16","author":"AF Phillips","year":"2025","journal-title":"Nat Commun"},{"key":"pone.0334147.ref020","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Z Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0334147.ref021","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"P Bankhead","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0334147.ref022","doi-asserted-by":"crossref","first-page":"16059","DOI":"10.1038\/s41598-024-66945-7","article-title":"Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2\/glutamine pathway","volume":"14","author":"P Thongpon","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0334147.ref023","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"KJ Livak","year":"2001","journal-title":"Methods"},{"issue":"7","key":"pone.0334147.ref024","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"J Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"7","key":"pone.0334147.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006407","article-title":"The regulation of MS-KIF18A expression and cross talk with estrogen receptor","volume":"4","author":"M Zusev","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"pone.0334147.ref026","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jcb.21000","article-title":"MS-KIF18A, a kinesin, is associated with estrogen receptor","volume":"100","author":"G Luboshits","year":"2007","journal-title":"J Cell Biochem"},{"issue":"6","key":"pone.0334147.ref027","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12672-018-0349-2","article-title":"The importance of CYP19A1 in estrogen receptor-positive cholangiocarcinoma","volume":"9","author":"W Kaewlert","year":"2018","journal-title":"Horm Cancer"},{"issue":"8","key":"pone.0334147.ref028","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-012-1207-1","article-title":"Estrogen is increased in male cholangiocarcinoma patients\u2019 serum and stimulates invasion in cholangiocarcinoma cell lines in vitro","volume":"138","author":"T Hunsawong","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"pone.0334147.ref029","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/biom13020326","article-title":"Comprehensive pan-cancer analysis of KIF18A as a marker for prognosis and immunity","volume":"13","author":"T Liu","year":"2023","journal-title":"Biomolecules"},{"issue":"3","key":"pone.0334147.ref030","article-title":"A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma","volume":"14","author":"Z Gao","year":"2019","journal-title":"PLoS One"},{"key":"pone.0334147.ref031","doi-asserted-by":"crossref","first-page":"114697","DOI":"10.1016\/j.biopha.2023.114697","article-title":"Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology","volume":"162","author":"W Chen","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"pone.0334147.ref032","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","author":"T Kendall","year":"2019","journal-title":"Liver Int"},{"key":"pone.0334147.ref033","doi-asserted-by":"crossref","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: insights and implications","volume":"164","author":"M Nigam","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"pone.0334147.ref034","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"H Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"pone.0334147.ref035","article-title":"Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos","author":"B Sripa","year":"2011","journal-title":"Acta Trop"},{"issue":"7","key":"pone.0334147.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040201","article-title":"Liver fluke induces cholangiocarcinoma","volume":"4","author":"B Sripa","year":"2007","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0334147.ref037","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.parint.2011.06.011","article-title":"Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis","volume":"61","author":"P Yongvanit","year":"2012","journal-title":"Parasitol Int"},{"issue":"2","key":"pone.0334147.ref038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s42764-024-00126-8","article-title":"KIF18A as a potential biomarker to distinguish different breast cancer subtypes based on receptor status","volume":"5","author":"C Berkel","year":"2024","journal-title":"Genome Instab Dis"},{"key":"pone.0334147.ref039","first-page":"6383685","article-title":"Kinesin family member 18A (KIF18A) contributes to the proliferation, migration, and invasion of lung adenocarcinoma cells in vitro and in vivo","volume":"2019","author":"F-T Chen","year":"2019","journal-title":"Dis Markers"},{"issue":"3","key":"pone.0334147.ref040","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3892\/ol.2016.4823","article-title":"Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer","volume":"12","author":"M Kasahara","year":"2016","journal-title":"Oncol Lett"},{"issue":"17","key":"pone.0334147.ref041","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.18632\/aging.205027","article-title":"KIF18A improves migration and invasion of colorectal cancer (CRC) cells through inhibiting PTEN signaling","volume":"15","author":"Y Liu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"pone.0334147.ref042","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.12659\/MSM.917352","article-title":"Expression of KIF18A is associated with increased tumor stage and cell proliferation in prostate cancer","volume":"25","author":"H Zhang","year":"2019","journal-title":"Med Sci Monit"},{"issue":"10","key":"pone.0334147.ref043","doi-asserted-by":"crossref","first-page":"104142","DOI":"10.1016\/j.drudis.2024.104142","article-title":"Exploration of inhibitors targeting KIF18A with ploidy-specific lethality","volume":"29","author":"Q Chen","year":"2024","journal-title":"Drug Discov Today"},{"issue":"1","key":"pone.0334147.ref044","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10555-024-10225-3","article-title":"KIF18A inhibition: the next big player in the search for cancer therapeutics","volume":"44","author":"AS Mohd Amin","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"pone.0334147.ref045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives","volume":"72","author":"F Corti","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"pone.0334147.ref046","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"B Hoesel","year":"2013","journal-title":"Mol Cancer"},{"issue":"20","key":"pone.0334147.ref047","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1111\/febs.13894","article-title":"TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-\u03baB pathway-mediated inflammatory responses","volume":"283","author":"B Liu","year":"2016","journal-title":"FEBS J"},{"key":"pone.0334147.ref048","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"C Porta","year":"2014","journal-title":"Front Oncol"},{"issue":"8","key":"pone.0334147.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106056","article-title":"Aberrant expression of NF-\u03baB in liver fluke associated cholangiocarcinoma: implications for targeted therapy","volume":"9","author":"W Seubwai","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"pone.0334147.ref050","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/carcin\/bgq134","article-title":"Kif18A is involved in human breast carcinogenesis","volume":"31","author":"C Zhang","year":"2010","journal-title":"Carcinogenesis"},{"issue":"1","key":"pone.0334147.ref051","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbrc.2013.07.032","article-title":"Targeted deletion of Kif18a protects from colitis-associated colorectal (CAC) tumors in mice through impairing Akt phosphorylation","volume":"438","author":"H Zhu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"pone.0334147.ref052","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/CBM-240074","article-title":"KIF18A promotes cervical squamous cell carcinoma progression by activating the PI3K\/AKT pathway through upregulation of CENPE","volume":"41","author":"F Sun","year":"2024","journal-title":"Cancer Biomark"},{"issue":"22","key":"pone.0334147.ref053","doi-asserted-by":"crossref","first-page":"31892","DOI":"10.18632\/oncotarget.7441","article-title":"A positive feedback loop involving EGFR\/Akt\/mTORC1 and IKK\/NF-kB regulates head and neck squamous cell carcinoma proliferation","volume":"7","author":"Z Li","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0334147.ref054","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"Y He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0334147.ref055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2011.10.016","article-title":"CYR61 controls p53 and NF-\u03baB expression through PI3K\/Akt\/mTOR pathways in carboplatin-induced ovarian cancer cells","volume":"315","author":"K-B Lee","year":"2012","journal-title":"Cancer Lett"},{"issue":"7","key":"pone.0334147.ref056","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/13543784.2021.1916912","article-title":"Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs","volume":"30","author":"JJ Marin","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"pone.0334147.ref057","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The multifaceted role of chromosomal instability in cancer and its microenvironment","volume":"174","author":"SF Bakhoum","year":"2018","journal-title":"Cell"},{"issue":"1","key":"pone.0334147.ref058","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41576-024-00761-7","article-title":"Chromosomal instability as a driver of cancer progression","volume":"26","author":"X Chen","year":"2025","journal-title":"Nat Rev Genet"},{"issue":"1","key":"pone.0334147.ref059","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-024-01767-7","article-title":"The two sides of chromosomal instability: drivers and brakes in cancer","volume":"9","author":"R Hosea","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"pone.0334147.ref060","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"HA Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"pone.0334147.ref061","doi-asserted-by":"crossref","first-page":"114199","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population","volume":"208","author":"M Rimini","year":"2024","journal-title":"Eur J Cancer"},{"issue":"8","key":"pone.0334147.ref062","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"D-Y Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"pone.0334147.ref063","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"RK Kelley","year":"2023","journal-title":"Lancet"},{"issue":"10391","key":"pone.0334147.ref064","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/S0140-6736(23)00767-5","article-title":"Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer","volume":"401","author":"S Slater","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"pone.0334147.ref065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"C Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"pone.0334147.ref066","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"AM Goodman","year":"2017","journal-title":"Mol Cancer Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:24:57Z","timestamp":1760549097000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334147"}},"subtitle":[],"editor":[{"given":"Kishor","family":"Pant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":66,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334147","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}